BioSyngen Pte Ltd
BioSyngen Pte Ltd
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Early phase 1 | 2024-10-16 | NCT06645314 | |
| BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder | Not yet recruiting | Early phase 1 | 2024-10-16 | NCT06645301 | |
| A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Not applicable | 2024-10-16 | NCT06643910 | |
| Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Site, liver disorder, neoplasm | Not yet recruiting | Early phase 1 | 2023-12-18 | NCT06173726 | |
| BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, neoplasm | Recruiting | Early phase 1 | 2023-12-01 | NCT06152757 |